Prospective bone ultrasound patterns during childhood acute lymphoblastic leukemia treatment

被引:14
|
作者
Mussa, Alessandro [1 ]
Bertorello, Nicoletta [2 ]
Porta, Francesco [1 ]
Galletto, Chiara [2 ]
Nicolosi, Mario Guido [3 ]
Manicone, Rosaria [2 ]
Corrias, Andrea [1 ]
Fagioli, Franca [2 ]
机构
[1] Univ Turin, Regina Margherita Children Hosp, Dept Pediat Endocrinol & Diabetol, Div Pediat Endocrinol, I-10126 Turin, Italy
[2] Univ Turin, Dept Pediat Oncohematol, I-10126 Turin, Italy
[3] St Anna Hosp, Dept Gynecol & Obstet, Turin, Italy
关键词
Pediatrics; Childhood leukemia; Bone complications; Quantitative ultrasound; Fractures; PHALANGEAL QUANTITATIVE ULTRASOUND; YOUNG-ADULT SURVIVORS; HUMAN FINGER PHALANGES; MINERAL DENSITY; FRACTURE RISK; CHILDREN; TURNOVER; PROPAGATION; GEOMETRY; GROWTH;
D O I
10.1016/j.bone.2009.12.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Bone impairment is a well-known complication in childhood acute lymphoblastic leukemia (ALL) survivors but less is known about bone dynamics during ALL therapy. We longitudinally assessed by Quantitative Ultrasound (QUS) skeletal modifications during this treatment. Materials and methods: Forty-four newly diagnosed ALL children underwent bone measurement by QUS parameters BTT (Bone Transmission Time) and AD-SoS (Amplitude-Dependent Speed of Sound), mainly reliant on bone density and cortical thickness, respectively. Measurements were performed at diagnosis, and 6, 12, and 24 months thereafter. The occurrence of skeletal complications such as fractures, vertebral collapse, osteonecrosis, and osteopenia was related to measurement outcome. Results: A rapid deterioration of bone properties measured by Bit and AD-SoS was evident in the first semester of therapy (p<0.001). Subsequently, the next measurements were characterized by progressive uncoupling of the two QUS parameters (p<0.001). These were both significantly reduced at the end of therapy (p<0.001). Twelve subjects with in-treatment skeletal complications displayed an almost two-fold decrease of both parameters (p<0.001). Bit decreasing more than 1 Standard Deviation (SD) over 6 months of therapy was able to predict skeletal complication occurrence (p<0.001). Conclusion: This report represents the largest longitudinal cohort systematically submitted to bone condition assessment from the beginning to the end of therapy for childhood ALL. Bone deterioration occurs early and persists throughout therapy, consistent with bone properties uncoupling. This pattern possibly reflects an initial impairment of both mineral density and cortical thickness with a subsequent recovery of this latter. QUS permits an early detection of bone deterioration and related skeletal complications in childhood ALL. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:1016 / 1020
页数:5
相关论文
共 50 条
  • [31] Infection-related complications during treatment for childhood acute lymphoblastic leukemia
    Inaba, H.
    Pei, D.
    Wolf, J.
    Howard, S. C.
    Hayden, R. T.
    Go, M.
    Varechtchouk, O.
    Hahn, T.
    Buaboonnam, J.
    Metzger, M. L.
    Rubnitz, J. E.
    Ribeiro, R. C.
    Sandlund, J. T.
    Jeha, S.
    Cheng, C.
    Evans, W. E.
    Relling, M. V.
    Pui, C. -H.
    ANNALS OF ONCOLOGY, 2017, 28 (02) : 386 - 392
  • [32] PHARMACOKINETICS OF TRIMETHOPRIM DURING PROPHYLACTIC TREATMENT IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    SONNEVELD, P
    HAHLEN, K
    VANDERSTEUYT, K
    NOOTER, K
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 209 - 209
  • [33] Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukemia
    Poulsen, A
    Demeny, AK
    Plum, CB
    Nielsen, KG
    Schmiegelow, K
    MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 37 (01): : 20 - 23
  • [34] METHOTREXATE POLYGLUTAMATES DURING INTERVAL THERAPY OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT
    de Beaumais, Adam T.
    Fakhoury, M.
    Medard, Y.
    Zhang, D.
    Yakouben, K.
    Dervieux, T.
    Jacqz-Aigrain, E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 130 - 130
  • [35] Survey of humoral immunity during treatment for childhood acute lymphoblastic leukemia (ALL)
    Pourtsidis, Apostolos
    Baka, Margarita
    Bouhoutsou, Despina
    Pourtsidis, Apostolos
    Doganis, Dimitrios
    Varvoutsi, Maria
    Kallergi, Constantina
    Douladiris, Nikolaus
    Synodinou, Maria
    Saxoni-Papageorgiou, Fotini
    Kosmidis, Helen
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 461 - 461
  • [36] Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia
    Farrow, AC
    Buchanan, GR
    Zwiener, RJ
    Bowman, WP
    Winick, NJ
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) : 1560 - 1566
  • [37] METHOTREXATE POLYGLUTAMATES DURING INTERVAL THERAPY OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT
    De Beaumais, T. Adam
    Fakhoury, M.
    Medard, Y.
    Zhang, D.
    Yakouben, K.
    Dervieux, T.
    Jacqz-Aigran, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S51 - S51
  • [38] Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia
    Rivera, GK
    Zhou, YM
    Hancock, ML
    Gajjar, A
    Rubnitz, J
    Ribeiro, RC
    Sandlund, JT
    Hudson, M
    Relling, M
    Evans, WE
    Pui, CH
    CANCER, 2005, 103 (02) : 368 - 376
  • [39] BONE-MARROW RELAPSE IN ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD
    CORNBLEET, MA
    CHESSELLS, JM
    BRITISH MEDICAL JOURNAL, 1978, 2 (6130): : 104 - 106
  • [40] BONE-MARROW FIBROSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA OF CHILDHOOD
    HANN, IM
    EVANS, DIK
    MARSDEN, HB
    JONES, PM
    PALMER, MK
    JOURNAL OF CLINICAL PATHOLOGY, 1978, 31 (04) : 313 - 315